PAB 0.00% 0.7¢ patrys limited

Ann: Patrys Receives R&D Tax Incentive Refund, page-14

  1. 16,270 Posts.
    lightbulb Created with Sketch. 743
    Any potential partners can see we are funded to go to trial.

    Hi

    I am pleased to advise that Patrys wholly-owned subsidiary Nucleus Therapeutics Pty Ltd has received a $3.35 million R&D Tax Incentive Refund for the 2021/2022 financial year.

    With this rebate and our current cash balance, our Company can confidently advance our first deoxymabs into the clinic by the end of 2023.

    We are grateful for the support of the Australian Government through this initiative, which motivates investment in Australian-led innovation.

    If you have any questions, please contact our team via the details below.

    Last edited by malmanu: 30/01/23
 
watchlist Created with Sketch. Add PAB (ASX) to my watchlist
(20min delay)
Last
0.7¢
Change
0.000(0.00%)
Mkt cap ! $14.40M
Open High Low Value Volume
0.7¢ 0.7¢ 0.7¢ $9.941K 1.420M

Buyers (Bids)

No. Vol. Price($)
2 51753 0.7¢
 

Sellers (Offers)

Price($) Vol. No.
0.8¢ 1638632 8
View Market Depth
Last trade - 14.08pm 28/06/2024 (20 minute delay) ?
PAB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.